PPT-Antiplatelet therapy in CAD

Minilecture Objectives Indications for Antiplatelet Therapy in patients with CAD and ACS Antiplatelet Therapy in the role of primary and secondary prevention of c ardiovascular events CAD amp the Vulnerable Plaque. V Kamakoti Department of Computer Science and Engineering Indian Institute of Technology Madras Chennai 600 036 India Email kamacsiitmernetin CAD for VLSI DESIGN I CAD for VLSI Design I Course Starts Here All The Best CAD for VLSI DESIGN I Evo Antiplatelet Guidelines. Antiplatelet. Therapy for . Vascular Prevention in Patients with Peripheral Arterial Disease. Working. Group. : A. Roussin, MD, FRCP; Thomas F. Lindsay, MD, CM. , FRCSC. Objectives. Therapy for Secondary Prevention . Beyond One Year . Following . ACS or PCI. Working Group. : . Anil Gupta MD, FRCPC, Pierre Theroux MD, FRCPC . Canadian Cardiovascular Society Antiplatelet Guidelines. Therapy for the Secondary Prevention of . Cerebrovascular. Disease. Working Group: . Ashfaq. . Shuaib. , MD, . FRCP; Philip . Teal, MD, FRCP. Canadian Cardiovascular Society . Antiplatelet Guidelines. Working Group: . Maria E. Wolfs, MD, FRCP; . Rémi. . Rabasa-Lhoret. , MD, PhD. Canadian Cardiovascular Society Antiplatelet . Guidelines. Objectives. Interpret . the . Canadian Cardiovascular Society Guideline recommendations regarding the use of antiplatelet . (. PTS). Aleksandra . Seledkova. . Perm National Research Polytechnic University. The comparison of existing CAD systems for designing the power supply systems. CAD . system. Circuit diagram. Calculation of electrical parameters. Antiplatelet Guidelines. . ANTIPLATELET THERAPY IN PATIENTS WITH CHRONIC KIDNEY DISEASE. Working. Group: . Neesh. . Pannu. , MD, SM, FRCP; Alan D. Bell, MD, CCFP. Interpret the Canadian Cardiovascular Society Guideline recommendations regarding the use antiplatelet . Stratified by Baseline CV Risk Category. Aspirin for Secondary Prevention of CV Disease. Anticoagulant Therapy in CAD. Warfarin -- WARIS-2. ATLAS ACS 2 -- TIMI 51. Rivaroxaban vs Placebo After ACS. COMPASS. Antiplatelet Therapy for Secondary Prevention in the First Year Following an Acute Coronary Syndrome Working Group: Jean-François Tanguay , MD, CSPQ, FRCP(C), FACC, FAHA, FESC; Michael P. Love, MB, ChB, MD, MRCP; and Robert C. Welsh, MD, FRCP, FACC Management of Anticoagulants & Antiplatelet Agents Pre and Post Endoscopy Thomas Savides, M.D. Professor of Clinical Medicine University of California, San Diego Disclosures None Learning Objectives 2D drawing programmes, 3D modelling software . Can help designers model and change ideas quickly. Can experiment with different colours and shapes. You can spot problems before making anything . CAM – is making using a computer and machine. Anticoagulant therapy. (n = . 124). CADISS. P. rimary outcome. : . Ipsilateral . stroke or all-cause mortality . for antiplatelet vs. anticoagulation: 2. % . vs. 1%; p . = . 0.63. Any stroke: 2% vs. 1%, . People with diabetes have a 2 to 4 fold higher risk of dying from cardiovascular disease. People with diabetes have a complex procoagulant state, which contributes to the increased risk of atheroscler 12. inhibitor to dual pathway inhibition with aspirin plus vascular-dose rivaroxaban: The Switching Anti-Platelet and Anti-Coagulant Therapy (SWAP-AC) Study. Luis Ortega-Paz, MD, PhD. 1. ; Francesco Franchi, MD.